Advertisement


Charles E. Geyer, Jr, MD, FACP, on the SOFT Trial

2014 San Antonio Breast Cancer Symposium

Advertisement

Charles E. Geyer, Jr, MD, FACP, of Massey Cancer Center, discusses abstract S3-08, “Randomized comparison of adjuvant tamoxifen plus ovarian function suppression vs tamoxifen in premenopausal women with hormone receptor–positive early breast cancer: Analysis of the SOFT trial,” presented by Prudence Francis, MD.



Related Videos

Breast Cancer

Prudence Francis, MD, and Hope Rugo, MD, on the Phase III SOFT Trial

Prudence Francis, MD, of Peter MacCallum Cancer Centre, and Hope Rugo, MD, of the University of California, San Francisco, discuss data from abstract S3-08,

Breast Cancer

Gunter von Minckwitz, MD, on the Phase III ICE Trial

Gunter von Minckwitz, MD, of the University of Frankfurt, offers his thoughts on abstract S3-04,

Breast Cancer

Matthew J. Ellis, MD, PhD, and Harold J. Burstein, MD, PhD, on Genome-Directed Therapeutics for Endocrine Therapy-Resistant ER-Positive Breast Cancer

Matthew J. Ellis, MD, PhD, of the Baylor College of Medicine discusses with Harold J. Burstein, MD, PhD, of the Dana-Farber Cancer Institute genome-directed therap...

Breast Cancer

Lisa A. Carey, MD, on the CALGB/Alliance 40603 Trial

Lisa A. Carey, MD, of the UNC Lineberger Comprehensive Cancer Center, addresses further analysis of data from abstract S4-05,

Breast Cancer

Lisa A. Carey, MD, on Pembrolizumab in Advanced Triple-Negative Breast Cancer

Lisa A. Carey, MD, of UNC Lineberger Comprehensive Cancer Center, offers her thoughts on abstract S1-09,


Advertisement



Advertisement